Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
- REGULATORY NEWS IN BRIEF -1-
January 15, 2001
- Changing OTC Business Strategy, Priority Shifts to Volume Retailers
January 15, 2001
- Welfide Transfers Infusion Fluid Business to Otsuka Pharmaceutical Factory, Inc
January 15, 2001
- OTC news on brief
January 15, 2001
- Suntory, Taisho to Codevelop SUN N8075 for Cerebral Infarction
January 15, 2001
- Sankyo, Mochida Tie Up with Riken
January 15, 2001
- Tanabe Licenses Out TR-14035 to SmithKline Beecham
January 15, 2001
- Asahi Chemical Invests US$9 Mil in Circe Biomedical
January 15, 2001
- Sumitomo Ties Up With Gene Logic
January 15, 2001
- Elan Obtains Approval for Botulinum Toxin B in US
January 15, 2001
- SBS Transfers Tagamet to Sumitomo
January 15, 2001
- NHI Medical Costs Map Not Reflecting Reality: JMARI
January 15, 2001
- SmithKline Beecham: Hycamtin Approved for Small Cell Lung Cancer
January 15, 2001
- New Health Ministry's Budget Totals \18 Trillion, +4.5% Over FY2000
January 15, 2001
- Fukujin Becomes Hokuho Iyaku's Major Shareholder
January 15, 2001
- Glaxo Wellcome Changes Its Name to Glaxo SmithKline, Relocates Head Office
January 15, 2001
- Arimidex Approved as 1st Drug Based on Bridging Studies in Japan
January 15, 2001
- Dainippon Starts Full Operation of New PMS Information System
January 15, 2001
- BUSINESS NEWS IN BRIEF -1-
January 15, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…